Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Free Report) – Research analysts at Edison Inv. Res issued their FY2025 earnings per share (EPS) estimates for Basilea Pharmaceutica in a note issued to investors on Thursday, March 27th. Edison Inv. Res analyst J. Prakash expects that the company will earn $4.76 per share for the year.
Basilea Pharmaceutica Price Performance
OTCMKTS:BPMUF opened at $54.00 on Monday. The company has a quick ratio of 3.27, a current ratio of 4.10 and a debt-to-equity ratio of 5.70. The company has a 50-day moving average of $52.97 and a 200-day moving average of $52.66. Basilea Pharmaceutica has a 52 week low of $38.60 and a 52 week high of $54.00.
About Basilea Pharmaceutica
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.
Featured Articles
- Five stocks we like better than Basilea Pharmaceutica
- Where to Find Earnings Call Transcripts
- 3 Buyable Stocks With Solid Bottoms Ready to Rebound
- What Are Growth Stocks and Investing in Them
- Advantage+ Shopping: Meta’s Fast Growing $20 Billion AI-Ads Star
- What Does a Stock Split Mean?
- Robotaxi News: What Tesla and Lyft Headlines Mean for Shares
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
